A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PF-05175157 After Administration Of Single Escalating Oral Doses Under Fasted And Fed Conditions In Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2011
At a glance
- Drugs PF 5175157 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- 22 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Mar 2011 New trial record